Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 3
2019 6
2020 4
2021 5
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year

Citations

3 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Conforti F, et al. Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778737
BACKGROUND: Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments. We did a systematic review
BACKGROUND: Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patient
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Duan J, et al. JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367. JAMA Oncol. 2020. PMID: 31876895 Free PMC article.
STUDY SELECTION: All randomized clinical trials that compared anti-PD-1 and anti-PD-L1 with standard treatment in patients with cancer were selected as candidates. Retrospective studies, single-arm phase 1/2 studies, and trials comparing anti-PD-1 and anti-PD-L1 wit …
STUDY SELECTION: All randomized clinical trials that compared anti-PD-1 and anti-PD-L1 with standard treatment in patients with ca
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S. Dafni U, et al. Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30. Lung Cancer. 2019. PMID: 31319971
This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare the efficacy of treatments including at least one immune-checkpoint inhibitor (ICI) with or without chemotherapy, as frontline therapy …
This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare t …
Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.
Hassler MR, Abufaraj M, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV, Schmidinger M, Karakiewicz PI, Shariat SF. Hassler MR, et al. Clin Genitourin Cancer. 2020 Apr;18(2):88-94.e2. doi: 10.1016/j.clgc.2019.09.004. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31668768
We aimed to assess the efficacy of immunotherapy according to patient gender in advanced kidney cancer. We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews …
We aimed to assess the efficacy of immunotherapy according to patient gender in advanced kidney cancer. We perfo …
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.
Conforti F, Pala L, Pagan E, Corti C, Bagnardi V, Queirolo P, Catania C, De Pas T, Giaccone G. Conforti F, et al. ESMO Open. 2021 Oct;6(5):100251. doi: 10.1016/j.esmoop.2021.100251. Epub 2021 Aug 26. ESMO Open. 2021. PMID: 34455288 Free PMC article. Review.
BACKGROUND: In our previous works, we demonstrated that patients' sex affects the efficacy of immune checkpoint inhibitors (ICIs) in patients with several advanced solid tumors. ...METHODS: We carried out a systematic review and meta
BACKGROUND: In our previous works, we demonstrated that patients' sex affects the efficacy of immune checkpoint inhibit …
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, Gelber RD, Goldhirsch A. Conforti F, et al. J Natl Cancer Inst. 2019 Aug 1;111(8):772-781. doi: 10.1093/jnci/djz094. J Natl Cancer Inst. 2019. PMID: 31106827 Free PMC article.
The second included all RCTs of first-line systemic treatment in advanced non-small cell lung cancer testing anti-PD-1/PD-L1 given either alone or combined with chemotherapy to assess the different efficacy of these two immunotherapeutic strategies according to p
The second included all RCTs of first-line systemic treatment in advanced non-small cell lung cancer testing anti-PD-1/PD-L1 given ei …
Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis.
Lai LT, Gu WG, Hu MB, Wang WJ, Wang SS, Huai YJ, Mei JH, Wang CL. Lai LT, et al. Aging (Albany NY). 2021 Jun 4;13(11):15413-15432. doi: 10.18632/aging.203100. Epub 2021 Jun 4. Aging (Albany NY). 2021. PMID: 34086601 Free PMC article.
Although disease susceptibility is known to differ between men and women, it is controversial whether the efficacy of immune checkpoint inhibitors for malignancies also differs between the sexes. We conducted a meta-analysis to explore the impact of sex
Although disease susceptibility is known to differ between men and women, it is controversial whether the efficacy of immune checkpoi …
Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
Xue C, Zheng S, Dong H, Lu X, Zhang X, Zhang J, Li J, Cui H. Xue C, et al. Front Oncol. 2021 Aug 26;11:627016. doi: 10.3389/fonc.2021.627016. eCollection 2021. Front Oncol. 2021. PMID: 34513654 Free PMC article.
METHODS: We performed this systematic review and meta-analysis of all potentially relevant studies retrieved from PubMed, EMBASE, and the Cochrane Library until June 2021, for eligible randomized controlled trials (RCTs) comparing immunotherapy
METHODS: We performed this systematic review and meta-analysis of all potentially relevant studies retrieved fro …
Platinum versus immunotherapy for unresectable esophageal cancer: A protocol for systematic review and meta analysis.
Qian J, Tong Z, Zhang Y, Chen C. Qian J, et al. Medicine (Baltimore). 2020 Dec 18;99(51):e23537. doi: 10.1097/MD.0000000000023537. Medicine (Baltimore). 2020. PMID: 33371077 Free PMC article.
Some clinical trials have reported that compared with traditional platinum-based chemotherapy, the use of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors alone can benefit patients and effectively prolong their overall survival. We compare the …
Some clinical trials have reported that compared with traditional platinum-based chemotherapy, the use of programmed death 1 (PD-1) and prog …
20 results